PF-03622905 

PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC₅₀s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases^[1].

PF-03622905 causes concentration-dependent inhibition of phospho-ERK1/2 formation, interleukin 8 release, and phospho-SHP2 levels with an IC₅₀ value 0.15 μM, 0.16 μM, and 35 nM, respectively^[1].
PF-03622905 shows low cytotoxicity at 1 μM against human umbilical vein endothelial cells with remaining cell viability at 83.3% viable^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

469.58

C₂₄H₃₅N₇O₃

1072100-15-2

O=C(C1=CC=CC=N1)NC2=NNC3=C2CN(C(N4C[C@H](N(C[C@@H]4C)CCC)CCO)=O)C3(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Stephan Grant, et al. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model. Eur J Pharmacol. 2010 Feb 10;627(1-3):16-25.  [Content Brief]